Northern Trust’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-197,896
Closed -$3.64M 4536
2020
Q4
$3.64M Sell
197,896
-12,567
-6% -$229K ﹤0.01% 2857
2020
Q3
$3.86M Buy
210,463
+15,182
+8% +$255K ﹤0.01% 2698
2020
Q2
$2.92M Buy
195,281
+27,894
+17% +$398K ﹤0.01% 2824
2020
Q1
$2.65M Buy
167,387
+3,306
+2% +$53.4K ﹤0.01% 2689
2019
Q4
$2.67M Buy
164,081
+3,806
+2% +$63.5K ﹤0.01% 2946
2019
Q3
$2.38M Sell
160,275
-9,998
-6% -$135K ﹤0.01% 3006
2019
Q2
$2.81M Buy
170,273
+8,101
+5% +$132K ﹤0.01% 2870
2019
Q1
$2.81M Buy
162,172
+70
+0% +$1.27K ﹤0.01% 2883
2018
Q4
$2.86M Sell
162,102
-2,213
-1% -$37.6K ﹤0.01% 2852
2018
Q3
$2.98M Buy
164,315
+82,557
+101% +$1.69M ﹤0.01% 2988
2018
Q2
$1.6M Buy
81,758
+43,778
+115% +$820K ﹤0.01% 3315
2018
Q1
$667K Buy
37,980
+7,076
+23% +$130K ﹤0.01% 3494
2017
Q4
$347K Buy
30,904
+868
+3% +$9.06K ﹤0.01% 3642
2017
Q3
$320K Hold
30,036
﹤0.01% 3659
2017
Q2
$263K Sell
30,036
-102,447
-77% -$903K ﹤0.01% 3713
2017
Q1
$1.56M Sell
132,483
-829
-0.6% -$10.1K ﹤0.01% 3192
2016
Q4
$1.75M Sell
133,312
-2,247
-2% -$30.1K ﹤0.01% 3163
2016
Q3
$1.97M Buy
135,559
+493
+0.4% +$7K ﹤0.01% 3081
2016
Q2
$1.62M Buy
135,066
+17,081
+14% +$274K ﹤0.01% 3153
2016
Q1
$2.2M Buy
117,985
+5,017
+4% +$83.2K ﹤0.01% 2930
2015
Q4
$2.43M Buy
112,968
+1,237
+1% +$26.1K ﹤0.01% 2943
2015
Q3
$1.89M Buy
111,731
+85,480
+326% +$2.13M ﹤0.01% 3085
2015
Q2
$985K Buy
26,251
+16,832
+179% +$543K ﹤0.01% 3353
2015
Q1
$296K Buy
+9,419
New +$255K ﹤0.01% 3759

Northern Trust's CBMG Position: Q1 2021 in Review

Northern Trust sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q1 2021, closing a stake of 197,896 shares — an estimated $3.64M sold.

Northern Trust first reported a position in CBMG in Q1 2015 and held it in 24 quarters. The position peaked at $3.86M in Q3 2020. 0 funds tracked by Wall St. Rank hold CBMG as of Q1 2021.

  • Northern Trust reported no remaining Cellular Biomedicine Group, Inc. position as of Q1 2021 after selling out during the quarter.
  • Northern Trust sold 197,896 Cellular Biomedicine Group, Inc. shares in Q1 2021, an estimated $3.64M.
  • Northern Trust first reported a position in Cellular Biomedicine Group, Inc. in Q1 2015 and held it in 24 quarters.
  • Northern Trust's Cellular Biomedicine Group, Inc. position peaked at $3.86M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q1 2021.

Based on Northern Trust's 13F filing for Q1 2021, filed 12 May 2021.